Eutropics Pharmaceuticals is a biomarker discovery, CLIA laboratory. We develop novel functional clinical diagnostic tests that recognize unique apoptosis signaling features of cancer cells from individual patients. The information indicates if a given patient is likely to have a meaningful response to a broad range of treatments. The ex vivo assays are developed with partnering pharmaceutical companies to select patients into clinical trials. In the future the developed tests will be used to help oncology physicians select best treatment options for their patients. The tests are functional predictive assays that are first in class and are protected by a substantive patent portfolio. The key components of the platform, Selective Measurement of Apoptosis Complex (SMAC-Dx) are biomarker antibodies that selectively bind to specific Bcl-2 family protein complexes. These complexes are known to be predictors of patient response.
Eutropics Pharmaceuticals is presenting as part of the NIH Innovation Zone.